Charles River Laboratories International, Inc. (CRL)

NYSE: CRL · Real-Time Price · USD
141.36
+4.39 (3.21%)
May 8, 2025, 4:00 PM EDT - Market closed
3.21%
Market Cap 6.94B
Revenue (ttm) 4.02B
Net Income (ttm) -31.56M
Shares Out 49.12M
EPS (ttm) -0.62
PE Ratio n/a
Forward PE 14.45
Dividend n/a
Ex-Dividend Date n/a
Volume 2,330,409
Open 139.44
Previous Close 136.97
Day's Range 139.43 - 143.47
52-Week Range 91.86 - 254.15
Beta 1.50
Analysts Hold
Price Target 184.00 (+30.16%)
Earnings Date May 7, 2025

About CRL

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use o... [Read more]

Sector Healthcare
IPO Date Jun 23, 2000
Employees 20,100
Stock Exchange NYSE
Ticker Symbol CRL
Full Company Profile

Financial Performance

In 2024, CRL's revenue was $4.05 billion, a decrease of -1.92% compared to the previous year's $4.13 billion. Earnings were $10.30 million, a decrease of -97.83%.

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for CRL stock is "Hold." The 12-month stock price forecast is $184.0, which is an increase of 30.16% from the latest price.

Price Target
$184.0
(30.16% upside)
Analyst Consensus: Hold
Stock Forecasts

News

S&P 500 Gains & Losses Today: Stocks Gain in Volatile Session as Markets React to Fed Meeting, Trump Trade Comments

The S&P 500 broke a two-session losing streak, rising Wednesday as stocks gained ground in volatile trading following the Federal Reserve's decision to keep interest rates unchanged.

1 day ago - Investopedia

Charles River Laboratories International, Inc. (CRL) Q1 2025 Earnings Call Transcript

Charles River Laboratories International, Inc. (NYSE:CRL) Q1 2025 Results Conference Call May 7, 2025 9:00 AM ET Company Participants Todd Spencer - Vice President, Investor Relations Jim Foster - Ch...

1 day ago - Seeking Alpha

Charles River Laboratories' Q1 Earnings Beat Consensus, Stock Trades Higher On Signs Of Demand Stabilization

Charles River Laboratories International Inc CRL stock is trading higher on Wednesday after the company released better than expected first-quarter 2025 earnings.

1 day ago - Benzinga

Charles River Stock Is Having Its Best Day in 13 Years. A Board Shake-Up and Business Review Will Help.

The biotech said its largest investor would conduct a ‘strategic review' as revenue continued to decline.

1 day ago - Barrons

Top Stock Moves Now: Charles River Labs, Disney, Supermicro, and More

U.S. equities were little changed at midday as the market awaited the Federal Reserve's interest-rate decision coming this afternoon. The Dow Jones Industrial Average was higher, the Nasdaq was lower,...

Other symbols: DISSMCI
1 day ago - Investopedia

Charles River to add new directors, review business in agreement with Elliott

Charles River Laboratories said on Wednesday it had reached an agreement with activist investor Elliott Investment Management and added four new directors to its board.

1 day ago - Reuters

Charles River Laboratories Announces First-Quarter 2025 Results

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces First-Quarter 2025 Financial Results.

1 day ago - Business Wire

Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value.

1 day ago - Business Wire

Exclusive: Charles River agrees with Elliott to add new directors, review business

Pharmaceutical company Charles River Laboratories has reached a settlement with activist investor Elliott Investment Management to add four new directors to its board and launch a strategic review of ...

1 day ago - Reuters

Charles River Announces Inaugural Advanced Therapy Incubator Program Cohort

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--The Charles River Incubator Program announces its first cohort, expediting the development of technologies and life-changing therapies for patie...

9 days ago - Business Wire

Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Ahead of AACR 2025, Charles River announces updates to its comprehensive portfolio to support the discovery and development of novel oncology dr...

16 days ago - Business Wire

Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories schedules first-quarter 2025 earnings release and conference call.

23 days ago - Business Wire

What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?

The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from traditional animal testing.

Other symbols: CERTSLP
27 days ago - Benzinga

Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform

WILMINGTON, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and Valo Health announce the identification of an advanceable product candidate for treatment of lupus and othe...

6 weeks ago - Business Wire

Charles River Laboratories to Present at Barclays Global Healthcare Conference

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at Barclays Global Healthcare Conference.

2 months ago - Business Wire

FairJourney Biologics Acquires Charles River Laboratories South San Francisco Facility

PORTO, Portugal & SAN FRANCISCO--(BUSINESS WIRE)--FairJourney Biologics S.A., leaders in the discovery and optimization of antibodies, today announced that it had completed the acquisition of the Sout...

2 months ago - Business Wire

Charles River Announces Agreement with Singapore General Hospital

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River to provide master cell banking and NGS testing services for SGH's cord blood derived allogeneic CAR-T cells.

2 months ago - Business Wire

Analyst Sees Charles River As Preclinical Leader But Maintains Neutral Stance

On Wednesday, Charles River Laboratories International Inc CRL reported fourth-quarter 2024 revenue of $1 billion, a decrease of 1.1% year over year, beating the consensus of $983.63 million.

2 months ago - Benzinga

Charles River Laboratories International, Inc. (CRL) Q4 2024 Earnings Call Transcript

Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2024 Earnings Call February 19, 2025 8:30 AM ET Company Participants Todd Spencer - Vice President, Investor Relations Jim Foster - Chair,...

2 months ago - Seeking Alpha

Charles River beats quarterly estimates on stable demand for drug development services

Charles River Laboratories on Wednesday beat fourth-quarter profit and revenue estimates, helped by stable demand for its drug discovery and development services from biotech clients.

2 months ago - Reuters

Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024 Results and Provides 2025 Guidance

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024 Results and Provides 2025 Guidance.

2 months ago - Business Wire

Charles River and Deciphex Extend Global Partnership to Expand Digital Pathology Offering with Exclusive Image Management Solutions

WILMINGTON, Mass. & DUBLIN--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and Deciphex focus on advancing image management solutions, while developing novel AI tools for toxicologic pathology.

3 months ago - Business Wire

Charles River Laboratories Schedules Fourth-Quarter 2024 Earnings and 2025 Guidance Release and Conference Call

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Schedules Fourth-Quarter 2024 Earnings and 2025 Guidance Release and Conference Call.

3 months ago - Business Wire

Charles River Expands Apollo™ Ecosystem, Offering Bespoke Client Experiences

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River expands Apollo ecosystem, offering bespoke client experiences that enable data-driven decision making.

3 months ago - Business Wire

Charles River and Akron Bio Announce Collaboration to Enhance Operations with Integration of CGMP Materials into Cell Therapy Platform

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Akron Bio (“Akron”), a leading supplier of critical materials and services for advanced therapies, to...

4 months ago - Business Wire